CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

Shares of Hims & Hers Health ( HIMS 12.82%) surged on Tuesday, closing the session up 5.25% after having been up by as much ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers is a newfangled telehealth company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one’s given the stock a heck of ride; way up and then all the ...